| abstract |
Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains and related products, methods and uses as improved vaccines against infection of respiratory syncytial virus (RSV virus). Specifically, a genetically engineered recombinant MVA vector comprising at least one nucleotide sequence encoding an antigenic determinant of a RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of a RSV nucleocapsid protein is provided herein. Also, there are products, methods, and uses thereof suitable for determining whether a subject is at risk of recurrent RSV infection, for example, for influencing an immune response in a subject or for diagnosing RSV infection. provided herein. |